Yearly Median Technologies liquidity contract statement contracted with AUREL BGC Company

We transform medical images into meaningful, actionable insights to help better diagnose, treat, and monitor patients. We deploy proprietary artificial intelligence, computer vision, and signal processing technologies to develop imaging tests and services, addressing life-threatening unmet medical needs.

With eyonis™ we are disrupting the management of serious diseases such as lung cancer, liver cancer, and NASH. We are deploying AI/ML Software as Medical Devices (SaMDs) to help health professionals diagnose patients earlier, treat them more effectively, and bring new hope. eyonis™ is currently under development.

Imaging Services for Clinical Trials

Median’s Imaging CRO business provides leading oncology clinical trial imaging services, empowering our life sciences partners to accelerate the development and delivery of life-saving cancer treatments with unmatched operational excellence and reliability. And we don’t stop there. We are forging the way when it comes to innovative imaging technology, leveraging the latest in AI-powered imaging intelligence to develop actionable insights for biopharma sponsors worldwide.

Learn More

Request a Demo

Press Release – For immediate release – 5:45pm CET

Under the liquidity contract entrusted by Median Technologies to AUREL BGC, the following resources were listed in the liquidity account as at December 31, 2017:

€ 205,848.52*
20,981 shares

For information, as at June 30, 2017, the following resources were listed in the liquidity account:

€ 174,357.93
9,607 shares

[*] The company made an additional contribution of 150,000 Euros on December 19^th, 2017

Back to press releases